A Safety Study of Mebendazole in Children 2 to 10 Years of Age
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to assess the safety and tolerability of mebendazole 500-mg chewable tablet formulation in a pediatric population. Mebendazole is a drug used for the treatment of soil-transmitted parasitic helminth (STH) (ie, parasitic worm) infections such as pinworm, whipworm, common roundworm, common hookworm, and American hookworm.
| Condition | Intervention | Phase |
|---|---|---|
|
Healthy Volunteers |
Drug: Mebendazole |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | An Open-Label, Single-Dose Study to Assess the Safety of 500-mg Mebendazole Chewable Formulation in Children 2 to 10 Years of Age, Inclusive |
- The number, severity, relationship to study drug, and type of adverse events reported. [ Time Frame: Baseline (Day 1) to the end of study (Day 3) or early withdrawal visit ] [ Designated as safety issue: No ]
- Change in physical examination [ Time Frame: Baseline (Day 1) to the end of study (Day 3) or early withdrawal visit ] [ Designated as safety issue: No ]
- Change in vital sign measurements [ Time Frame: Baseline (Day 1) to the end of study (Day 3) or early withdrawal visit ] [ Designated as safety issue: No ]
| Enrollment: | 397 |
| Study Start Date: | February 2010 |
| Study Completion Date: | March 2010 |
| Primary Completion Date: | March 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Mebendazole |
Drug: Mebendazole
Type= exact number, unit= mg, number= 500, form= chewable tablet, route= oral use. One mebendazole 500-mg chewable tablet taken on Day 1.
|
Detailed Description:
This is an open-label (identity of study drug will be known to study participant and investigator), single-center, single-dose, single-arm (ie, 1 treatment group) safety study. This study will consist of a screening visit on Day 1 at which time all study-related screening procedures will be performed. After all results are reviewed, children who meet all of the inclusion criteria and none of the exclusion criteria will be entered into the open-label phase of the study. A single mebendazole 500-mg chewable tablet will be administered on Day 1 and the children will remain at the study site so that adverse events can be recorded at approximately 30 minutes postdose. Study participants will return to the study site 3 days (plus or minus 1 day) postdose at which time adverse events will be recorded again. Safety will be monitored during the study by assessing adverse events by direct observation at 30 minutes after dosing and at 3 days (plus or minus 1 day) after dosing, by direct observation of the study participant, report by the parent or guardian, or both. On Day 1, a single mebendazole 500-mg chewable tablet will be chewed and swallowed by each study participant. If desired, study participants will be allowed to drink water when administered study drug.
Eligibility| Ages Eligible for Study: | 2 Years to 10 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Be an otherwise healthy child based on medical history, physical examination, vital signs, and concomitant medications and live in a high-prevalence area where parasite infection is endemic (ie, Prevalent in or peculiar to a particular locality, region, or people)
- Have teeth and be able to chew the mebendazole chewable tablet
- Girls must be premenarchal
- Parent(s)/guardians of study participants (or their legally-accepted representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to have their child participate in the study
Exclusion Criteria:
- Have a history of clinically significant liver or renal insufficiency
- cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic (eg, anemia), rheumatologic, psychiatric, or metabolic disturbances that, in the opinion of the investigator, renders the candidate not suitable for mebendazole treatment
- Have a suspected massive intestinal parasitic infection, based on history and physical findings, as determined by the principal investigator
- Have any condition that, in the opinion of the investigator, would compromise the well-being of the study participant or the study or prevent the study participant from meeting or performing study requirements
Contacts and Locations| Study Director: | Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
More Information
Additional Information:
No publications provided
| Responsible Party: | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| ClinicalTrials.gov Identifier: | NCT01173562 History of Changes |
| Other Study ID Numbers: | CR017419, MEBENDAZOLGAI3002 |
| Study First Received: | July 29, 2010 |
| Last Updated: | August 28, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:
|
Healthy volunteers Parasitic Diseases Mebendazole (VERMOX) Anthelmintics |
Antiparasitic Agents Soil-transmitted helminth (STH) infections Pediatric |
Additional relevant MeSH terms:
|
Antiparasitic Agents Mebendazole Piperazine Piperazine citrate Anti-Infective Agents Therapeutic Uses Pharmacologic Actions |
Antinematodal Agents Anthelmintics Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |
ClinicalTrials.gov processed this record on June 17, 2013